HCA Healthcare, Inc. (HCA) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in HCA Healthcare (HCA) by buying shares or fractional shares at any major US broker, through a health-care or hospital ETF that holds it, or as one holding in a thematic basket. HCA is the largest for-profit hospital operator in the United States, running a network of acute-care hospitals plus a fast-growing set of outpatient sites like surgery centers, urgent care, and freestanding emergency rooms across concentrated local markets. The thesis rests on scale: HCA's size gives it cost, staffing, and payer-negotiation advantages that smaller systems struggle to match, driving steady admissions growth and strong cash flow it returns through buybacks and dividends. The single biggest thing to understand is that HCA's revenue depends heavily on government and commercial reimbursement, so policy shifts like ACA subsidy expirations and Medicaid changes can swing its earnings. As of November 20, 2026 the shares closed near $473, roughly flat for the year (up about 0.6%) after a third quarter that beat EPS estimates by about 9%.
HCA stock price
As of 2026-11-20, HCA Healthcare, Inc. (HCA) last closed at $475.57, down 3.1% over the past year. Over the past 52 weeks it has traded between $361.32 and $545.13.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or HCA Healthcare, Inc.'s investor relations page. Walnut is informational, not investment advice.
HCA key stats
At $475.57 on November 20, 2026, HCA Healthcare, Inc. (HCA) has a market cap of $99.3B, a P/E of 15.8 on trailing earnings (15.2 on forward earnings) and a dividend yield of 0.66%. It next reports earnings around January 26, 2027 (estimated).
- Market cap
- $99.3B
- P/E (trailing)
- 15.8
- P/E (forward)
- 15.2
- EPS (trailing 12 months)
- $30.15
- Dividend yield
- 0.66%
- Beta
- 1.10
- Next earnings
- around January 26, 2027 (estimated)
Market cap, P/E and yield are measured at the $475.57 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with HCA Healthcare, Inc. (HCA)?
The last two weeks for HCA Healthcare, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- HCA closed at $475.57 on November 20, 2026, down 4.7% over the past five trading days (from $499.05).
- HCA Healthcare, Inc. next reports quarterly results around January 26, 2027 (estimated).
- On November 18, 2026, JP Morgan raised its target to $475.00 from $425.00 (Neutral).
HCA Healthcare, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
HCA Healthcare, Inc. (HCA) latest quarter
HCA Healthcare reported revenue of $19.8 billion for Q3 2026, up 4% from a year earlier (HCA Healthcare, Oct 27, 2026).
Source: HCA Healthcare Q3 2026 results, Oct 27, 2026. Full earnings breakdown
What does HCA Healthcare, Inc. (HCA) do?
HCA Healthcare is the largest for-profit hospital system in the United States, operating a network of acute-care hospitals alongside surgery centers, urgent-care clinics, freestanding emergency rooms, and physician clinics. Its strategy centers on building dense local networks in growing Sun Belt and suburban markets, where controlling a large share of care lets it negotiate better rates with commercial insurers, recruit physicians, and spread fixed costs. In the first quarter of 2026 HCA reported revenue of about $19.1 billion, up roughly 4% year over year, with net income near $1.6 billion and diluted EPS of about $7.15, and it reaffirmed full-year 2026 guidance of roughly $76.5 billion to $80.0 billion in revenue and $15.55 billion to $16.45 billion in adjusted EBITDA. The second quarter, ended June 30, was stronger: revenue of about $20.2 billion, up roughly 9%, net income near $1.7 billion and EPS of $7.59 against a $7.50 estimate. The third quarter, ended September 30, brought revenue of about $19.9 billion, up roughly 3.6% and above the roughly $19.3 billion expected, net income near $1.6 billion and EPS of $7.22, well ahead of the $6.63 estimate and the fifth straight beat. Trailing twelve-month revenue now stands near $78.7 billion, with net income of about $6.8 billion.
The defining issue for 2026 is reimbursement policy. HCA has warned that the lapse of enhanced ACA marketplace subsidies plus Medicaid payment changes could pressure adjusted EBITDA by several hundred million dollars, with a $150 million ACA-related hit already flagged in the first quarter. Management is running a multi-year resilience plan to offset part of the impact through cost control, productivity, and pricing. At the same time HCA is accelerating its outpatient shift, adding lower-cost ambulatory sites (including outpatient partnerships in markets like Charleston and an expanding breast-imaging footprint), and rolling out the Meditech Expanse electronic-record system across its facilities. It remains a heavy generator of free cash flow, about $3.9 billion over the last twelve months, which it directs toward capital projects, dividends, and large share repurchases.
The stock has swung widely this year, trading between about $354 and $557 over 52 weeks. As of November 20, 2026 it closed near $473, up about 0.6% year to date, about 10% over three months and roughly flat (down about 0.6%) over one year, after JPMorgan's active value ETF made HCA its lead purchase in mid-November. The 22 analysts covering it carry a mean target near $486. The next report, for the fourth quarter, is expected around January 26, 2027, with analysts expecting about $8.21 of EPS on roughly $20.0 billion of revenue.
What's driving HCA Healthcare, Inc. (HCA)?
1. Scale and local-market density
HCA's core advantage is its size and its strategy of dominating individual markets rather than spreading thin. Owning a large share of hospital capacity in a metro area strengthens its hand in negotiations with commercial insurers, helps recruit and retain physicians and nurses, and lets it spread fixed costs across more volume. That scale is difficult for smaller regional systems to replicate and underpins its steadier margins, with an operating margin near 15% over the last twelve months.
2. Outpatient and ambulatory expansion
Care is shifting out of inpatient hospital beds toward lower-cost settings, and HCA is investing heavily in ambulatory surgery centers, urgent-care clinics, freestanding emergency rooms, imaging, and physician practices. Building out these sites captures patients earlier, feeds referrals into its hospitals, and defends share against standalone outpatient competitors. Growth beyond the hospital walls is a central plank of its multi-year capital plan, and recent moves include outpatient partnerships in Charleston and more breast-imaging capacity.
3. Cash generation and capital returns
HCA produces large and relatively predictable free cash flow, about $3.9 billion over the twelve months to September 2026 on roughly $11.2 billion of operating cash flow, which it deploys into new facilities, technology like the Meditech Expanse rollout, dividends, and sizable share buybacks. Consistent repurchases have steadily shrunk the share count and supported per-share earnings growth even when revenue growth is moderate. Capital allocation is a meaningful part of the total-return story.
4. Resilience plan against policy headwinds
Facing an estimated adjusted-EBITDA hit from ACA subsidy expiration and Medicaid payment changes, HCA is executing a multi-year resilience plan aimed at offsetting a large portion through productivity, cost discipline, AI and workflow automation, and payer and service-mix management. It reaffirmed 2026 guidance despite the headwinds, then beat EPS estimates again in the second and third quarters; the September quarter came in at $7.22 against a $6.63 consensus that had assumed a year-over-year dip. Management execution on these offsets remains a key swing factor, and analysts expect EPS growth of only about 4% in 2027.
What are the risks to HCA Healthcare, Inc. (HCA)?
The dominant risk is reimbursement and health-care policy. HCA depends on a mix of commercial, Medicare, and Medicaid payers, and the expiration of enhanced ACA marketplace subsidies plus Medicaid payment changes could pressure adjusted EBITDA by several hundred million dollars, with more uninsured and self-pay patients raising bad-debt and charity-care costs. Labor is a structural cost pressure: nursing and physician wages, contract-labor use, and staffing shortages can compress margins quickly. Supply, drug, and equipment costs, including exposure to tariffs and supply-chain disruption, add further cost volatility. HCA also carries substantial debt from years of buybacks, about $52.4 billion against roughly $1.0 billion of cash as of September 2026, so higher interest rates raise financing costs. Revenue growth slowed to about 3.6% in the third quarter from about 9% in the second, and analysts model only about 3% revenue growth in 2027, so per-share gains lean increasingly on buybacks and cost control. Litigation, regulatory scrutiny of billing and pricing practices, and local competition from nonprofit systems and physician-owned outpatient centers round out the risk set.
What is the HCA Healthcare, Inc. (HCA) forecast?
22 analysts publish price targets on HCA, averaging $485.68 as of November 2026, or +2.1% against the $475.57 share price on November 20, 2026. The published targets run from $380.00 to $585.00, a moderate spread, and the ratings split 15 buy, 9 hold, 2 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full HCA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is HCA a buy or a sell?
We give no verdict on HCA Healthcare, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Scale and local-market density. HCA's core advantage is its size and its strategy of dominating individual markets rather than spreading thin. The most optimistic published target, $585.00, assumes this works close to its best case.
The case against. The dominant risk is reimbursement and health-care policy. The most pessimistic target, $380.00, is roughly what HCA is worth if this bites instead.
Read the full bull and bear case on HCA, including what would have to change to break either one. Walnut is not an investment adviser.
Has HCA Healthcare, Inc. (HCA) split its stock?
No. HCA Healthcare, Inc. (HCA) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is HCA Healthcare, Inc. (HCA) valued?
Market cap, P/E and dividend yield at today's price are in the HCA key stats above. The business figures below come from HCA Healthcare, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$78.7 billion; Q3 2026 ~$19.9 billion, up ~3.6% year over year
- Net income (TTM): ~$6.8 billion, ~8.6% net margin
- Q3 2026 EPS vs estimate: $7.22 vs $6.63
- Full-year 2026 guidance (given with Q1): Revenue ~$76.5 billion to $80.0 billion; adjusted EBITDA ~$15.55 billion to $16.45 billion
- Dividend: ~$3.12 a year, yield ~0.7%
- Balance sheet: ~$52.4 billion of debt vs ~$1.0 billion of cash
As of November 2026: At about $473 on November 20, 2026, HCA trades near 15.7x trailing and 15.1x forward earnings and under 10x EV/EBITDA, the multiple of a steady, cash-generative operator more than a high-growth stock, so it reflects reimbursement stability and buyback-driven per-share growth more than rapid revenue expansion. Analysts expect 2026 EPS of about $30.09 rising to about $31.29 in 2027, roughly 4% growth. The biggest variable is still policy: the 2026 guidance bakes in an ACA-subsidy and Medicaid hit that management is partly offsetting, and the 2027 outlook that usually arrives with the January report will show how much of it carries over.
Who competes with HCA Healthcare, Inc. (HCA)?
For-profit hospital operators
Tenet Healthcare, Universal Health Services, and Community Health Systems are HCA's closest publicly traded peers, running acute-care hospitals and, in Tenet's case, a large ambulatory surgery business. HCA's much larger scale, market density, and profitability generally set it apart, but all share exposure to the same reimbursement and labor-cost dynamics.
Nonprofit and regional health systems
In most local markets HCA competes against large nonprofit systems and academic medical centers such as Ascension, CommonSpirit, and regional players. These systems often have tax advantages and community ties, and the balance of local share against them shapes HCA's pricing power in each metro market.
Outpatient and specialty providers
As care shifts out of hospitals, HCA increasingly competes with standalone ambulatory surgery centers, physician-owned clinics, urgent-care chains, and freestanding emergency operators, including names like Surgery Partners. HCA's own ambulatory expansion is partly a response, aiming to capture this lower-cost care rather than cede it to specialists.
What stocks are similar to HCA Healthcare, Inc. (HCA)?
Other names that sit close to HCA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in HCA Healthcare, Inc. (HCA)
There are three common ways to get HCA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HCA sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where HCA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on HCA Healthcare, Inc. (HCA)
HCA is the scale leader in US hospital care, a roughly $99 billion company generating large, steady cash flows it returns to shareholders, but its earnings are exposed to reimbursement policy. In 2026 it is absorbing an ACA-subsidy and Medicaid hit while leaning into outpatient growth, and so far it has kept beating estimates, most recently with third-quarter EPS of $7.22 against $6.63 expected even as revenue growth slowed to about 3.6%. The question is how well its resilience plan holds up against those policy headwinds into 2027.
More on HCA Healthcare, Inc. (HCA)
Whether HCA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HCA a buy or a sell?, and where the stock could go from here in the HCA stock forecast.
For income investors, whether HCA pays a dividend and how the payout looks is covered in does HCA pay a dividend? And to weigh HCA against a peer, read the full side-by-side comparisons: HCA vs THC and HCA vs UHS.
Wondering how HCA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about HCA Healthcare, Inc.
Ask Walnut's AI anything about HCA and see how it fits what you own.
FAQ
Is HCA a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is HCA's scale leadership, steady admissions and cash flow, growing outpatient network, consistent buybacks and dividends, and a run of five straight earnings beats through the third quarter of 2026. The bear case is heavy exposure to reimbursement policy, with ACA subsidy expiration and Medicaid changes pressuring 2026 earnings, plus labor costs, about $52 billion of debt, and revenue growth that slowed to about 3.6% in the latest quarter. Weigh both against your portfolio.
What does HCA Healthcare actually do?
+
HCA operates the largest for-profit hospital network in the United States, running acute-care hospitals along with surgery centers, urgent-care clinics, freestanding emergency rooms, and physician practices. It earns revenue by providing medical care and billing commercial insurers, Medicare, Medicaid, and patients. Its strategy is to build dense networks in individual local markets, mostly in growing Sun Belt and suburban regions.
How do ACA subsidies and Medicaid affect HCA?
+
A large share of HCA's patients are covered by government or subsidized insurance. HCA has warned that the lapse of enhanced ACA marketplace subsidies and Medicaid payment changes could reduce adjusted EBITDA by several hundred million dollars in 2026, with a $150 million ACA-related hit flagged in the first quarter. More uninsured patients can also raise bad-debt and charity-care costs.
How did HCA do in its latest quarter?
+
For the quarter ended September 30, 2026, HCA reported revenue of about $19.9 billion, up roughly 3.6% year over year and above the roughly $19.3 billion expected, net income of about $1.6 billion, and EPS of $7.22, well ahead of the $6.63 consensus. It has now beaten EPS estimates in five straight quarters. The fourth-quarter report is expected around January 26, 2027, with analysts expecting about $8.21 of EPS on roughly $20.0 billion of revenue.
How has HCA stock performed in 2026?
+
As of the November 20, 2026 close near $473, HCA was up about 0.6% year to date, about 10% over three months and about 1% over the past month, and roughly flat (down about 0.6%) over one year. Its 52-week range is about $354 to $557. The 22 analysts covering it carry a mean target near $486 and a buy consensus, an opinion rather than a forecast Walnut endorses.
Does HCA pay a dividend?
+
Yes, HCA pays a quarterly dividend, currently about $3.12 a year, which works out to a yield of roughly 0.7% at November 2026 prices and a payout ratio near 10% of earnings. The company directs much of its cash flow toward share buybacks in addition to the dividend, so repurchases have historically been a larger part of its capital return than the payout. Always check the latest declared dividend and yield before assuming any payout.
How is HCA growing beyond hospitals?
+
HCA is accelerating its outpatient strategy, investing in ambulatory surgery centers, urgent-care clinics, freestanding emergency rooms, imaging, and physician clinics as care shifts to lower-cost settings. These sites capture patients earlier and feed referrals into its hospitals. The company is also rolling out the Meditech Expanse electronic-record system to improve data and support value-based care negotiations.
What are the main risks of investing in HCA?
+
The central risk is reimbursement and health-care policy, including ACA subsidy expiration and Medicaid payment changes that pressure earnings. Labor costs for nurses and physicians, supply and drug costs including tariff exposure, and a substantial debt load add further risk. Litigation, regulatory scrutiny of billing, and competition from nonprofit systems and outpatient providers also matter. Q1 2026 already reflected some of the policy headwind, and revenue growth slowed to about 3.6% in the third quarter.
How can I get exposure to HCA through an ETF?
+
HCA appears in many broad health-care sector and hospital or medical-services ETFs, where it sits among the large care-provider names. ETF exposure spreads single-stock risk across dozens of holdings but dilutes how much any HCA move affects you. Always check a fund's holdings and weighting before assuming meaningful exposure to HCA specifically.
Who are HCA's main competitors?
+
Among publicly traded for-profit operators, HCA competes with Tenet Healthcare, Universal Health Services, and Community Health Systems. In local markets it faces large nonprofit systems such as Ascension and CommonSpirit and academic medical centers. As care moves outpatient, it also competes with standalone surgery centers, urgent-care chains, and physician-owned clinics for lower-acuity procedures.
Why does HCA carry so much debt?
+
HCA has funded years of large share buybacks and capital investment partly with borrowing, leaving it with about $52.4 billion of debt as of September 2026. That leverage can boost per-share earnings when the business performs, but it raises financing costs when interest rates are high and reduces flexibility if cash flow weakens. The debt is a structural feature of its capital-allocation model worth watching.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with HCA Healthcare, Inc.'s investor relations page or your broker before making investment decisions.